These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17513310)

  • 81. A bystander effect observed in boron neutron capture therapy: a study of the induction of mutations in the HPRT locus.
    Kinashi Y; Masunaga S; Nagata K; Suzuki M; Takahashi S; Ono K
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):508-14. PubMed ID: 17418970
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy.
    Mortensen MW; Björkdahl O; Sørensen PG; Hansen T; Jensen MR; Gundersen HJ; Bjørnholm T
    Bioconjug Chem; 2006; 17(2):284-90. PubMed ID: 16536457
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Microdistributions of prospective BNCT-compound CuTCPH in tissue sections with a heavy ion microbeam.
    Stoliar P; Kreiner AJ; Debray ME; Caraballo ME; Valda AA; Davidson J; Davidson M; Kesque JM; Somacal H; DiPaolo H; Burlon AA; Ozafrán MJ; Vázquez ME; Minsky D; Heber EM; Trivillin VA; Schwint AE
    Appl Radiat Isot; 2004 Nov; 61(5):771-4. PubMed ID: 15308142
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Boron detection from blood samples by ICP-AES and ICP-MS during boron neutron capture therapy.
    Linko S; Revitzer H; Zilliacus R; Kortesniemi M; Kouri M; Savolainen S
    Scand J Clin Lab Invest; 2008; 68(8):696-702. PubMed ID: 18609119
    [TBL] [Abstract][Full Text] [Related]  

  • 85. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors.
    Detta A; Cruickshank GS
    Cancer Res; 2009 Mar; 69(5):2126-32. PubMed ID: 19244126
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A conditional mouse model for malignant mesothelioma.
    Jongsma J; van Montfort E; Vooijs M; Zevenhoven J; Krimpenfort P; van der Valk M; van de Vijver M; Berns A
    Cancer Cell; 2008 Mar; 13(3):261-71. PubMed ID: 18328429
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Boron neutron capture therapy for an explanted organ: the logistical challenges.
    Wittig A; Moss R; Kaiser GM; Malago M; Nievaart V; Sauerwein WA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S302-5. PubMed ID: 19386503
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Microlocalization of lipophilic porphyrins: non-toxic enhancers of boron neutron-capture therapy.
    Smilowitz HM; Slatkin DN; Micca PL; Miura M
    Int J Radiat Biol; 2013 Aug; 89(8):611-7. PubMed ID: 23484623
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Comparison of BNCT and GdNCT efficacy in treatment of canine cancer.
    Mitin VN; Kulakov VN; Khokhlov VF; Sheino IN; Arnopolskaya AM; Kozlovskaya NG; Zaitsev KN; Portnov AA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S299-301. PubMed ID: 19428264
    [TBL] [Abstract][Full Text] [Related]  

  • 90. 10B-editing 1H-detection and 19F MRI strategies to optimize boron neutron capture therapy.
    Capuani S; Porcari P; Fasano F; Campanella R; Maraviglia B
    Magn Reson Imaging; 2008 Sep; 26(7):987-93. PubMed ID: 18486394
    [TBL] [Abstract][Full Text] [Related]  

  • 91. closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.
    Betzel T; Hess T; Waser B; Reubi JC; Roesch F
    Bioconjug Chem; 2008 Sep; 19(9):1796-802. PubMed ID: 18712900
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Treatment of murine tumors using dual-frequency ultrasound in an experimental in vivo model.
    Barati AH; Mokhtari-Dizaji M; Mozdarani H; Bathaie SZ; Hassan ZM
    Ultrasound Med Biol; 2009 May; 35(5):756-63. PubMed ID: 19195770
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
    Ampollini L; Soltermann A; Felley-Bosco E; Lardinois D; Arni S; Speck RF; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):457-62. PubMed ID: 19162494
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Study on the compounds containing 19F and 10B atoms in a single molecule for the application to MRI and BNCT.
    Hattori Y; Asano T; Niki Y; Kondoh H; Kirihata M; Yamaguchi Y; Wakamiya T
    Bioorg Med Chem; 2006 May; 14(10):3258-62. PubMed ID: 16460951
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Application of carbon-ion beams or gamma-rays on primary tumors does not change the expression profiles of metastatic tumors in an in vivo murine model.
    Tamaki T; Iwakawa M; Ohno T; Imadome K; Nakawatari M; Sakai M; Tsujii H; Nakano T; Imai T
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):210-8. PubMed ID: 19362239
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A method to build an analytic model of the 10B(n,alpha)7Li reaction rate space distribution for boron neutron capture therapy (BNCT).
    Morand J; Moss R; Hachem S; Sauerwein W
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S149-52. PubMed ID: 19375922
    [TBL] [Abstract][Full Text] [Related]  

  • 98. An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd/boron multimodal probes for MRI guided BNCT.
    Alberti D; Deagostino A; Toppino A; Protti N; Bortolussi S; Altieri S; Aime S; Geninatti Crich S
    J Control Release; 2018 Jun; 280():31-38. PubMed ID: 29730155
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comments to article: Henriksson R et al., Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA) Radiother Oncol (2008).
    H-Stenstam B
    Radiother Oncol; 2008 Aug; 88(2):287-8; author reply 288. PubMed ID: 18617284
    [No Abstract]   [Full Text] [Related]  

  • 100. eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival.
    Siegele B; Cefalu C; Holm N; Sun G; Tubbs J; Meschonat C; Odaka Y; DeBenedetti A; Ghali GE; Chu Q; Mathis JM; Li BD
    J Surg Res; 2008 Jul; 148(1):83-9. PubMed ID: 18570935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.